Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker that has completed Phase II clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating atrial fibrillation and angina. The company was founded in 2003 and is headquartered in Montréal, Canada. The company trades on NASDAQ exchange. The company headquarter is located in Montreal, QC. The company was established in the 2003.

TickerMIST
Long NameMilestone Pharmaceuticals Inc.
Short NameMilestone Pharmaceuticals